Nivolumab
FDA approves Opdivo for initial treatment of advanced gastrointestinal cancers
The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.
Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset
A combination of nivolumab and ipilimumab induced significant antitumor activity among men with metastatic castration-resistant prostate cancer and a positive immunogenic signature, according to results of the phase 2 NEPTUNES trial.
Opdivo demonstrates positive results in patients with upper GI cancers
Chronic adverse events more common than thought after adjuvant immunotherapy for melanoma
Chronic immune-related adverse events appeared more common than previously thought among patients with stage III to stage IV melanoma who received adjuvant anti-PD-1 therapy, according to study results published in JAMA Oncology.
Relatlimab-nivolumab combination extends PFS in metastatic melanoma
A trial designed to evaluate the addition of relatlimab to nivolumab for untreated metastatic or unresectable melanoma met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.
Neoadjuvant combination immunotherapy ‘promising’ for early-stage NSCLC
Neoadjuvant combination immunotherapy improved outcomes for patients with operable non-small cell lung cancer, according to results of the randomized phase 2 NEOSTAR trial.
Adjuvant nivolumab significantly extends DFS in high-risk bladder cancer
Adjuvant nivolumab extended DFS compared with placebo among patients with high-risk, muscle invasive urothelial carcinoma, according to results of the phase 3 CheckMate 274 trial presented at Genitourinary Cancers Symposium.
Nivolumab prolongs PFS, OS in relapsed malignant mesothelioma
Nivolumab significantly prolonged PFS and OS compared with placebo for patients with relapsed malignant mesothelioma, according to findings presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Top in hem/onc: Updates in colorectal cancer
A recent study presented at the Gastrointestinal Cancers Symposium revealed low health-related quality of life scores among young adult survivors of colorectal cancer. It was the top story in hematology/oncology last week.